Analysis
Function Health has raised $450 million in growth financing from General Catalyst's Customer Value Fund (CVF), the healthcare-focused investment vehicle that ties capital to revenue milestones rather than writing a traditional priced equity check. The round comes just eight months after Function closed a $298 million Series B that valued the Austin-based preventive-health platform at $2.5 billion, and it arrives as the company pushes past 500,000 members and more than 100 million lab tests logged since its 2023 launch.
Function's pitch has stayed consistent since its early-2023 beta: combine lab testing, medical imaging and AI-driven interpretation into a single subscription that lets consumers track biomarkers most primary-care visits never touch. What's changed is the platform's shape. In May 2025 the company acquired Ezra, an AI-enabled medical-imaging startup, and used the deal to launch an $899 full-body MRI scan for members -- turning Function from a blood-panel company into something closer to a diagnostics network.
That expansion accelerated further in 2026: Function acquired Getlabs, a home-and-mobile lab-draw company, in April, and SuppCo, a supplements platform, in May, stitching testing, imaging and follow-on treatment into one vertically integrated stack. The move puts Function in more direct competition with Everlywell and Thorne on testing, with Prenuvo on imaging, and increasingly with subscription longevity clinics like Fountain Life that bundle diagnostics with concierge care.
“Coming eight months after a $2.5 billion Series B, the CVF round lets Function keep scaling without resetting its valuation mark in a choppier growth-equity market.”
The financing structure is itself a signal. General Catalyst's Customer Value Fund model extends capital against a company's own revenue and unit economics rather than diluting founders at a fixed valuation -- a structure General Catalyst has increasingly used for capital-intensive, high-growth healthcare platforms it wants to keep backing without forcing a new priced round every few months. Coming eight months after a $2.5 billion Series B, the CVF round lets Function keep scaling without resetting its valuation mark in a choppier growth-equity market.
For consumer-health founders, Function's acquisition pace -- three deals in thirteen months -- is the more instructive data point than the check size. Vertical integration, not point-solution differentiation, is becoming the defensible moat in preventive health, and investors are rewarding platforms that can own the full testing-to-treatment loop rather than a single diagnostic wedge.
The risk is regulatory and reimbursement exposure: full-body MRI screening and expansive lab panels remain contested among clinicians over false positives and unnecessary follow-up care, and Function's model depends on consumers paying out of pocket in a category insurance mostly doesn't cover. Watch whether Function pursues a fourth acquisition to round out its stack, and whether CVF-style revenue-based financing becomes the template other GPs use to back capital-intensive health platforms without a full re-price.
